Clinical efficacy of ulinastatin on severe acute pancreatitis and its effect on serum levels of inflammatory cytokines

Objective To observe the effect of alinastatin on the treatment of severe acute pancreatitis and level of the serum inflammatory factors. Methods Eighty-six patients with severe acute pancreatitis were randomly divided into observation group and control group, with 43 cases in each group. The control group was given common treatment, the observation group underwent the conventional treatment combined with ulinastatin. Acute physiology and chronic health evaluation (APACHEⅡ), clinical symptoms disappeared time, serum tumor necrosis factor-α(TNF-α), interleukin-6(IL-6) and interleukin-8(IL-8) were compared between two groups after 7 d of treatment. Results After 7 d of treatment, the APACHE Ⅱ score of observation group was 8.93±2.47, which was significantly lower than that of control group (11.61±2.58, P<0.01). The disappearing time of abdominal pain, bloating, nausea, vomiting and other clinical symptoms in observation group were shorter than those in control group. The levels of TNF-α, IL-6 and IL-8 in the two groups after treatment significantly decreased (P<0.01), and the levels of all inflammatory factors in observation group were significantly lower than those in control group after treatment (P<0.01). Conclusions Ulinastatin in the treatment of severe acute pancreatitis can rapidly improve the clinical symptoms, reduce levels of serum inflammatory factors, with significant clinical effect. Key words: Ulinastatin; Severe acute pancreatitis; Inflammatory factors